66015-25-6

Basic information

• Product Name: ((6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid
• Synonyms: ((6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid
• CAS NO: 66015-25-6
• Molecular Formula: C₁₈H₁₃Cl₂FO₄
• Molecular Weight: 383.1978
• Mol File: 66015-25-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 548.6°Cat760mmHg
• Flash Point: 285.6°C
• Appearance: /
• Density: 1.468g/cm³
• Vapor Pressure: 7.21E-13mmHg at 25°C
• Refractive Index: 1.608
• CAS DataBase Reference: ((6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: ((6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid(66015-25-6)
• EPA Substance Registry System: ((6,7-dichloro-2-(4-fluorophenyl)-2-methyl-1-oxo-5-indanyl)oxy)acetic acid(66015-25-6)

Safety Data

• Hazardous Substances Data: 66015-25-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C18H13Cl2FO4/c1-18(10-2-4-11(21)5-3-10)7-9-6-12(25-8-13(22)23)15(19)16(20)14(9)17(18)24/h2-6H,7-8H2,1H3,(H,22,23)

Upstream product

• 53107-36-1 1-(2,3-dichloro-4-methoxyphenyl)-2-bromo-2-methyl-1-propanone 
• 66015-43-8 2-(4-fluorophenyl)-2-methyl-5-methoxy-6,7-dichloro-1-indanone 
• 53107-37-2 1-(2,3-dichloro-4-methoxyphenyl)-2-methylene-1-propanone 
• 53107-35-0 2',3',-Dichloro-4'-methoxyisobutyrophenone 
• 1984-59-4 2,3-dichloroanisole 
• 54196-91-7 6,7-dichloro-5-methoxy-2-methyl-1-indanone 
• 66015-50-7 6,7-dichloro-2-p-fluorophenyl-2,3-dihydro-5-hydroxy-2-methyl-1H-inden-1-one 
• 105-36-2 ethyl bromoacetate 

Relevant articles and documents

(1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio) alkanoic acids, and derivatives thereof

[1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio)]aklanoic acid, derivatives thereof, their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. Also disclosed are processes for the preparation of such [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio)]alkanoic acids, pharmaceutical compositions comprising therapeutically effective amounts of such compounds and methods of treatment comprising administering such compounds and compositions.